SG11201907043VA - Novel lactic acid bacteria and use thereof - Google Patents

Novel lactic acid bacteria and use thereof

Info

Publication number
SG11201907043VA
SG11201907043VA SG11201907043VA SG11201907043VA SG11201907043VA SG 11201907043V A SG11201907043V A SG 11201907043VA SG 11201907043V A SG11201907043V A SG 11201907043VA SG 11201907043V A SG11201907043V A SG 11201907043VA SG 11201907043V A SG11201907043V A SG 11201907043VA
Authority
SG
Singapore
Prior art keywords
strain
spp
lactic acid
acid bacteria
present
Prior art date
Application number
SG11201907043VA
Inventor
Dong-Hyun Kim
Myung Joo Han
Original Assignee
Univ Industry Cooperation Group Kyung Hee Univ
Navipharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Industry Cooperation Group Kyung Hee Univ, Navipharm Co Ltd filed Critical Univ Industry Cooperation Group Kyung Hee Univ
Publication of SG11201907043VA publication Critical patent/SG11201907043VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52Adding ingredients
    • AHUMAN NECESSITIES
    • A21BAKING; EDIBLE DOUGHS
    • A21DTREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D8/00Methods for preparing or baking dough
    • A21D8/02Methods for preparing dough; Treating dough prior to baking
    • A21D8/04Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes
    • AHUMAN NECESSITIES
    • A21BAKING; EDIBLE DOUGHS
    • A21DTREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D8/00Methods for preparing or baking dough
    • A21D8/02Methods for preparing dough; Treating dough prior to baking
    • A21D8/04Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes
    • A21D8/045Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes with a leaven or a composition containing acidifying bacteria
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/12Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/12Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/127Fermented milk preparations; Treatment using microorganisms or enzymes using microorganisms of the genus lactobacteriaceae and other microorganisms or enzymes, e.g. kefir, koumiss
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00Chewing gum
    • A23G4/06Chewing gum characterised by the composition containing organic or inorganic compounds
    • A23G4/12Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/02Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10Cereal-derived products
    • A23L7/104Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745Bifidobacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00Lactic or propionic acid bacteria
    • A23V2400/11Lactobacillus
    • A23V2400/169Plantarum
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00Lactic or propionic acid bacteria
    • A23V2400/51Bifidobacterium
    • A23V2400/533Longum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11Medicinal preparations comprising living procariotic cells
    • A61K2035/115Probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/722Chitin, chitosan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732Pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733Fructosans, e.g. inulin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225Lactobacillus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225Lactobacillus
    • C12R2001/25Lactobacillus plantarum

Abstract

A particular Bifidobacterium spp. strain or particular Lactobacillus spp. strain according to the present invention is isolated from excrement of a human or cabbage kimchi, and thus is highly safe and has physiological activities such as an immunity regulatory effect and an inflammation reaction inhibiting effect. Therefore, the particular Bifidobacterium spp. strain or particular Lactobacillus spp. strain according to the present invention may be used as a material for regulating immunity and inhibiting inflammation reactions, and may be also used as a functional food and drug material useful for preventing, alleviating or treating rhinitis, atopy, asthma, etc. which are allergic diseases. Representative Drawing FIG. 65
SG11201907043VA 2017-01-31 2018-01-31 Novel lactic acid bacteria and use thereof SG11201907043VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170013632 2017-01-31
PCT/KR2018/001359 WO2018143678A1 (en) 2017-01-31 2018-01-31 Novel lactic acid bacteria and use thereof

Publications (1)

Publication Number Publication Date
SG11201907043VA true SG11201907043VA (en) 2019-08-27

Family

ID=63040871

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10202107425VA SG10202107425VA (en) 2017-01-31 2018-01-31 Novel lactic acid bacteria and use thereof
SG11201907043VA SG11201907043VA (en) 2017-01-31 2018-01-31 Novel lactic acid bacteria and use thereof
SG10201913050RA SG10201913050RA (en) 2017-01-31 2018-01-31 Novel lactic acid bacteria and use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202107425VA SG10202107425VA (en) 2017-01-31 2018-01-31 Novel lactic acid bacteria and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913050RA SG10201913050RA (en) 2017-01-31 2018-01-31 Novel lactic acid bacteria and use thereof

Country Status (11)

Country Link
US (2) US11660321B2 (en)
JP (2) JP6839298B2 (en)
KR (2) KR101999259B1 (en)
CN (2) CN116676222A (en)
AU (2) AU2018216532B2 (en)
BR (1) BR112019015806A2 (en)
CA (2) CA3052134C (en)
MX (2) MX2019009079A (en)
RU (1) RU2752157C2 (en)
SG (3) SG10202107425VA (en)
WO (1) WO2018143678A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7015674B2 (en) * 2017-10-27 2022-02-15 日清食品ホールディングス株式会社 Regulatory T cell differentiation inducer and differentiation induction method
CN109498660A (en) * 2018-11-23 2019-03-22 江南大学 A kind of application for the lactobacillus plantarum CCFM8610 that can alleviate atopic dermatitis
KR102074445B1 (en) * 2018-12-12 2020-02-06 주식회사 비피도 Bifidobacterium longum RAPO for improvement, prevention or treatment of rheumatoid arthritis and composition comprising the same
CN109652349B (en) * 2019-02-25 2021-03-02 江南大学 Bifidobacterium longum capable of relieving atopic dermatitis and application thereof
WO2021040335A1 (en) * 2019-08-23 2021-03-04 연세대학교 산학협력단 Novel symbiotic strain having resistance under reactive oxygen condition and use thereof
KR102254310B1 (en) * 2019-10-02 2021-05-21 주식회사 고바이오랩 Lactobacillus Acidophilus KBL409 and Use Thereof
KR102263698B1 (en) * 2019-11-29 2021-06-09 롯데칠성음료주식회사 A mixture of Lactobacillus plantarum LRCC5195 and isomaltooligosaccharide having ameliorating or improving atopic dermatitis
CN110960562B (en) * 2019-12-31 2020-10-16 广州市爱百伊生物技术有限公司 Probiotic composition with anti-allergy effect
KR102325947B1 (en) * 2020-02-05 2021-11-15 주식회사 에이치이엠파마 A novel strain of lactobacillus sakei hem224, and composition for inflammatory or treating inflammatory and asthmatic comprising the strain or its culture fluid
WO2021166285A1 (en) * 2020-02-18 2021-08-26 AuB株式会社 Novel bacterium belonging to genus bifidobacterium and composition comprising same
CN111419883B (en) * 2020-03-13 2023-08-04 广州柏芳生物科技有限公司 Preparation method of nasal spray for treating allergic rhinitis
KR102162470B1 (en) 2020-03-19 2020-10-06 주식회사 비피도 Food composition for alleviation of Sjogren's syndrome and pharmaceutical composition with Bifidobacterium pseudocatenulatum C-RAPO (KCTC13986BP), Bifidobacterium bifidum ATT (KCTC13474BP)
CN111647526B (en) * 2020-05-18 2022-08-05 深圳华大基因农业控股有限公司 Lactobacillus plantarum SD-H9, probiotic microbial inoculum thereof and application thereof
KR102154255B1 (en) * 2020-05-22 2020-09-09 (주)녹십자웰빙 Composition for prevention or treatment of respiratory diseases or inflammation induced by particulate matter comprising novel lactic acid bacteria
JP7143044B2 (en) * 2020-06-23 2022-09-28 カゴメ株式会社 A composition for improving symptoms of allergic rhinitis, a composition for improving QOL deterioration caused by symptoms of allergic rhinitis, and a composition for suppressing sneezing caused by symptoms of allergic rhinitis
JP2022042042A (en) * 2020-09-02 2022-03-14 日清食品ホールディングス株式会社 Bifidobacterium inhibiting il-17 production
KR20220069248A (en) * 2020-11-20 2022-05-27 가톨릭대학교 산학협력단 Composition for Theragnosis of Scleroderma containing Bifidobacterium sp. as Active Ingredient
JPWO2022131192A1 (en) * 2020-12-16 2022-06-23
WO2022171654A1 (en) * 2021-02-09 2022-08-18 Lactobio A/S Method for treating atopic disorders
KR102268125B1 (en) * 2021-02-09 2021-06-22 주식회사 락토메이슨 A novel strain of bifidobacterium longum lm1024 derived from korean infants, and composition for relieving premenstrual syndrome comprising the strain or its culture fluid
KR102294442B1 (en) 2021-02-17 2021-08-27 주식회사 메디오젠 Infant and child origin lactic acid bacteria Lactobacillus plantarum MG4555 and composition comprising the lactic acid bacteria for enhancing intestine activity, anti-oxidant and anti-obesity
KR102294437B1 (en) 2021-02-17 2021-08-27 주식회사 메디오젠 Infant and child origin lactic acid bacteria Lactobacillus plantarum MG4553 and composition comprising the lactic acid bacteria for enhancing intestine activity, anti-oxidant and anti-obesity
KR102360233B1 (en) * 2021-03-26 2022-02-09 (주)바이오일레븐 Lactobacillus fermentum having effects of preventing or improving oral disease and use thereof
KR102445903B1 (en) * 2021-07-06 2022-09-22 롯데제과 주식회사 Lactobacillus plantarum LRCC5314 having an effect of blood glucose lowering-activity and controlling stress and its application
CN115466689B (en) * 2022-02-09 2023-06-16 中国科学技术大学 Probiotic composition for preventing and/or treating metabolic diseases and application thereof
CN115181698B (en) * 2022-06-28 2023-09-08 广东粤港澳大湾区国家纳米科技创新研究院 Probiotic composition and application thereof
CN115364127A (en) * 2022-07-06 2022-11-22 华南理工大学 Lactobacillus plantarum and prebiotics compound with regulating effect on immunosuppressed mice
KR102568093B1 (en) * 2023-02-07 2023-08-22 주식회사 바이오뱅크힐링 Composition for preventing or treating allergic diseases comprising Bifidobacterium longum as an active ingredient

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29150A (en) * 1999-01-15 2001-08-02 Entpr Ireland Cs USE OF LACTOBACILLUS SALIVARIUS
KR20050076374A (en) * 2004-01-20 2005-07-26 김수남 Utility products comprising soy bean extract fermented by lactic acid bacteria inhibiting ammonia production, allergy, atopy and thereof method
JP5273695B2 (en) * 2005-03-03 2013-08-28 株式会社明治 Allergy prevention and / or treatment agent containing bifidobacteria as an active ingredient
RU2440123C2 (en) 2005-10-06 2012-01-20 Проби Аб Lactobacillus application for treating viral infections
KR100715730B1 (en) 2005-11-15 2007-05-08 연세대학교 산학협력단 24A novel Bifidobacterium longum A24 with anti-bacterial activity against toxigenic pathogens
MX2008010422A (en) 2006-02-15 2008-10-27 Nestec Sa Use of bifidobacterium longum for the prevention and treatment of inflammation.
KR20080075971A (en) * 2007-02-14 2008-08-20 (주)네오팜 Probiotics combined preparations
JP5538209B2 (en) * 2007-03-28 2014-07-02 アリメンタリー・ヘルス・リミテッド Probiotic Bifidobacterium strain
US8658153B2 (en) * 2007-10-20 2014-02-25 Universite De Liege Bifidobacterial species
DK2808024T3 (en) * 2009-06-19 2019-06-11 Dupont Nutrition Biosci Aps Bifidobacteria for the treatment of congestive heart failure
KR101178217B1 (en) * 2009-10-28 2012-09-07 씨제이제일제당 (주) Novel lactobacillus plantarum and compositions comprising the same
WO2011058535A1 (en) * 2009-11-11 2011-05-19 Alimentary Health Limited Probiotic bifidobacterium strain
CA2787544C (en) 2010-01-28 2019-07-09 Ab-Biotics S.A. Probiotic composition for use in the treatment of bowel inflammation
JP4942831B2 (en) 2010-03-19 2012-05-30 株式会社キティー Antiallergic composition
ES2606679T3 (en) 2012-07-05 2017-03-27 Centro Nacional De Tecnologia Y Seguridad Alimentaria. Laboratorio Dei Ebro Microparticles for the encapsulation of probiotics, obtaining and using them
KR101740583B1 (en) * 2014-02-17 2017-05-29 경희대학교 산학협력단 Novel lactic acid bacteria having anti-obesity effect and use thereof
US9587284B2 (en) * 2014-02-21 2017-03-07 Asian Probiotics and Prebiotics Ltd. Lactic acid bacterium having immunomodulatory and anti-allergic effects and pharmaceutical composition containing the same
KR20160069733A (en) * 2014-12-09 2016-06-17 (주)바이오리듬 Lactobacillus plantarum, K-1 BR on antiallergic properties, anti atopic dermatitis, anti rhinitis, anti pruritus. egulation of level of immunity, microbial agent
JP2016136890A (en) 2015-01-28 2016-08-04 株式会社ヤクルト本社 Enhancement method of interleukin 10 production inducing ability of lactic acid bacteria
KR20170032815A (en) * 2015-09-15 2017-03-23 경희대학교 산학협력단 Novel lactic acid bacteria and composition for preventing, improving or treating neurodegenerative diseases or cognitive dysfunction
KR101655778B1 (en) 2016-02-19 2016-09-09 대한민국 Lactobacillus plantarum K46 and composition comprising the same
KR101750468B1 (en) 2016-03-04 2017-06-27 주식회사 메디오젠 Composition comprising Lactobacillus fermentum MG901 or Lactobacillus plantarum MG989
KR101743044B1 (en) * 2016-06-28 2017-06-02 바이오제닉스코리아 주식회사 The Functional Health Food For Improving The Intestine Function and Environment and Enhencing Immunity

Also Published As

Publication number Publication date
SG10201913050RA (en) 2020-03-30
AU2021205078A1 (en) 2021-08-12
AU2018216532A1 (en) 2019-08-15
CN110494551A (en) 2019-11-22
RU2021118078A (en) 2021-08-31
WO2018143678A1 (en) 2018-08-09
KR20180089324A (en) 2018-08-08
JP2021078511A (en) 2021-05-27
SG10202107425VA (en) 2021-08-30
CA3052134A1 (en) 2018-08-09
KR101999259B1 (en) 2019-07-11
JP7124142B2 (en) 2022-08-23
RU2019127021A3 (en) 2021-03-02
US20220323515A1 (en) 2022-10-13
CN116676222A (en) 2023-09-01
BR112019015806A2 (en) 2020-03-31
RU2752157C2 (en) 2021-07-23
KR102036841B1 (en) 2019-10-25
KR20190082739A (en) 2019-07-10
RU2019127021A (en) 2021-03-02
JP6839298B2 (en) 2021-03-03
MX2023003416A (en) 2023-05-24
CA3052134C (en) 2023-01-03
RU2021118078A3 (en) 2022-01-19
CA3178100A1 (en) 2018-08-09
AU2021205078B2 (en) 2023-03-02
US20230355690A1 (en) 2023-11-09
US11660321B2 (en) 2023-05-30
AU2018216532B2 (en) 2021-06-03
MX2019009079A (en) 2019-09-26
CN110494551B (en) 2023-06-16
JP2020515240A (en) 2020-05-28

Similar Documents

Publication Publication Date Title
SG11201907043VA (en) Novel lactic acid bacteria and use thereof
PH12018500566A1 (en) Novel lactobacillus having various functions, and use thereof
NZ711771A (en) Compositions for treating or preventing or reducing the severity of clostridium difficile related diseases
MX2021016034A (en) Compositions and methods of treating a th2-mediated condition using prevotella.
MY197900A (en) Use of lactic acid bacteria to treat or prevent at least one of postnatal depression and postnatal anxiety
PH12018550110A1 (en) Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation
EP3483256A4 (en) Akkermansia muciniphila strain having effect of preventing or treating degenerative brain diseases or metabolic diseases, and use thereof
MX2018012208A (en) Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders.
MY201921A (en) Agent for preventing or treating fat-associated diseases and/or inflammation
MX2018010428A (en) Direct-fed microbials.
NZ745184A (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
WO2020008149A8 (en) Use of a roseburia intestinalis strain for the prevention and treatment of inflammatory bowel disease
NZ760204A (en) Hypolipidemic effects of bacillus coagulans
MX2018008643A (en) 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives.
PH12019501439A1 (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
PH12019550183A1 (en) Treatment of infant colic
MX2017007969A (en) Lactic acid bacteria and their use for the treatment of mastitis.
EP3661502A4 (en) Compounds for the prevention and treatment of medical disorders and uses thereof
IL278898A (en) Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
GEP20237507B (en) Selection and use of melatonin supporting bacteria to reduce infantile colic
PH12019502315A1 (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
WO2019022602A8 (en) Pharmaceutical composition for use in the treatment or prevention of vitamin deficiency and mineral deficiency in patients who have been subjected to gastric sleeve surgery
MX2021005334A (en) Chemical compounds.
MX2020001501A (en) Streptococcus australis as a biotherapeutics.
MX2019012153A (en) Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof.